Early recanalization and plasma brain natriuretic peptide as an indicator of left ventricular function after acute myocardial infarction

What Was Tested

Researchers studied BNP (Nesiritide) in this randomized controlled trial publication.

Although plasma brain natriuretic peptide (BNP) levels have been widely measured in patients with acute myocardial infarction (AMI), it is still uncertain whether the early recanalization modulates the levels and whether the levels can predict chronic stage left ventricular function.

This study was designed to elucidate these issues.

Who Took Part

The abstract describes 80 patients taking part.

By PubMed's age tags, the people studied were middle-aged adults, both men and women.

In 80 consecutive patients with AMI, plasma BNP levels were measured at admission and at 4 hours, 24 hours, 48 hours, and 1 month after admission.

How the Study Was Run

The design is described as randomized.

The patients were allocated by chance, so the BNP (Nesiritide) group and the comparison group should start out alike.

What Was Measured

Although plasma brain natriuretic peptide (BNP) levels have been widely measured in patients with acute myocardial infarction (AMI), it is still uncertain whether the early recanalization modulates the levels and whether the levels can predict chronic stage left ventricular function.

The subject headings attached to it are Angioplasty, Balloon, Coronary, Biomarkers, Fibrinolytic Agents, Myocardial Infarction, Natriuretic Peptide, Brain, Regression Analysis and Vascular Patency.

What This Means in Plain Language

The paper is a randomized study of BNP (Nesiritide) in 80 patients.

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2002 (American heart journal), a journal based in United States.

More context: the BNP (Nesiritide) compound page, all human trials.